Life Sciences

  • July 25, 2025

    1st Circ. Backs Ex-Pharma Director's $24M Disability Bias Win

    The First Circuit declined to scrap a $24 million verdict for a former lab director of a Thermo Fisher Scientific Inc. subsidiary who claimed she was fired for seeking alternative public speaking arrangements due to her anxiety, ruling the evidence presented supported the jury's verdict.

  • July 25, 2025

    Boutique Upadhye Tang Gets McDermott Life Sciences Partner

    A six-year veteran of McDermott Will & Emery LLP's Washington, D.C., team has moved his pharmaceutical patent litigation practice to Upadhye Tang LLP, a boutique that focuses on intellectual property and U.S. Food and Drug Administration matters.

  • July 24, 2025

    Trump Admin Asks Justices To Stay Block On NIH Grant Cuts

    The Trump administration on Thursday urged the U.S. Supreme Court to stay a district court's preliminary injunction so that the National Institutes of Health can resume terminating $783 million in grants, saying the lower court, under a recent high court ruling, lacked jurisdiction to make the government pay the grants.

  • July 24, 2025

    Genentech Seeks Win After $122M Biogen Royalties Mistrial

    Genentech Inc. urged a California federal court Wednesday to rule that Biogen MA Inc. owes $122 million in patent royalties and interest under the "only coherent construction" of their licensing deal, in a rare post-mistrial arrangement that will see the judge step in to deliver the verdict.

  • July 24, 2025

    NC Judge Reins In Row Over Clinical Trial Software Contract

    A 6-year-old breach of contract suit got pruned on its second trip to North Carolina's business court Wednesday, with defendant Pharmaceutical Research Associates Inc. winning partial summary judgment against former PRA employee Neil Raja and the healthcare technology company he founded, Value Health Solutions Inc.

  • July 24, 2025

    Pa. Court Backs Use Of DNA From Trash In 1995 Rape Case

    The Pennsylvania Superior Court on Thursday upheld the use of a John Doe warrant and decades-delayed DNA testing to identify and convict a man in 2024 for the violent rape of a Penn State student in 1995, saying in the precedent-setting opinion that police were allowed to collect DNA evidence from the man's trash years later.

  • July 24, 2025

    Sun Pharma Settles Consumer Price Fixing Case For $200M

    Sun Pharmaceuticals has agreed to a $200 million settlement with a class of consumers who claim that the company joined other generics makers in fixing drug prices.

  • July 24, 2025

    FTC May Join Intuitive Surgical Antitrust Appeal

    The Federal Trade Commission has asked the Ninth Circuit for extra time to decide if it will weigh in on a $140 million antitrust appeal involving Intuitive Surgical's da Vinci robot.

  • July 24, 2025

    Novo Nordisk Resolves Ozempic TM Suit Against Drugmaker

    Novo Nordisk has settled claims of trademark infringement and unfair trade practices against Connecticut drugmaker LIVation LLC over the latter's comparisons of its compounded drugs to the Danish pharmaceutical company's Ozempic medication.

  • July 24, 2025

    Florida Man Gets 14 Years For $78M Drug Diversion Scheme

    The purported leader of a Florida-based operation that diverted $78 million in pharmaceutical drugs was sentenced to more than a decade in federal prison after pleading guilty to conspiracy-related charges in connection with illegally purchasing medications meant for HIV or cancer and reselling them as legitimately obtained products.

  • July 24, 2025

    Life Sciences-Focused Venture Firm Wraps $290.2M Fund

    Australian life sciences-focused venture capital firm Brandon Capital on Thursday revealed that it closed its sixth fund with AU$439 million ($290.2 million) in tow.

  • July 24, 2025

    CapVest Seeks $11.7B Stake In Stada, Plus More Rumors

    British private equity firm CapVest Partners is looking to take a major stake in German drugmaker Stada Arzneimittel in a roughly $11.7 billion deal, Comedy Central's "South Park" creators have nabbed a $1.5 billion five-year streaming rights deal with Paramount, and ExxonMobil wants to explore deepwater blocks in Trinidad and Tobago for oil and gas. Here, Law360 breaks down these and other deal rumors from the past week.

  • July 24, 2025

    3rd Circ. Rules Philly Injection Site Equals Religious 'Person'

    A nonprofit battling government resistance to its planned safe drug injection site in Philadelphia can qualify for religious freedom protections, the Third Circuit said in a precedential opinion on Thursday, reasoning the organization meets the definition of a "person" practicing religion.

  • July 24, 2025

    Eli Lilly's Trademark Suit Not 'Abuse Of Process'

    A Washington federal judge has tossed out counterclaims by a pair of clinics being sued for trademark infringement by Eli Lilly & Co., saying the acts of filing the suit and making a settlement demand are not in themselves abuse of process.

  • July 23, 2025

    NJ Fed. Judge Pulls Opinion Flagged With Nonexistent Quotes

    A New Jersey federal judge on Wednesday withdrew his decision declining to dismiss a securities class action against CorMedix Inc. after an attorney for the biopharmaceutical firm pointed out the opinion contained "a series of errors," including nonexistent quotes and misstated decisions.

  • July 23, 2025

    FTC Wants PE Firm's Medical Device Coating Deal Put On Ice

    Private equity firm GTCR BC Holdings' $627 million merger with Surmodics will bring the previously fierce competition for medical device coatings to a grinding halt, the FTC says, which is all the more reason a federal court should block the deal while an agency challenge plays out.

  • July 23, 2025

    Meta Grabs Menstrual App Users' Data For Ads, Jury Told

    Meta collected sensitive medical information using the Flo Health menstrual cycle app and used that information to sell targeted ads, a computer security expert told a California jury Wednesday in a multibillion-dollar privacy class action brought on behalf of 13 million women.

  • July 23, 2025

    Astellas, Generics Scolded For 'Abusive' Discovery In IP Case

    A Delaware federal magistrate judge on Wednesday rebuked Astellas Pharma and makers of generic drugs for what she deemed exploitation of the discovery dispute process in the brand-name company's patent infringement case, calling their dozens of fights "not just excessive" but also "abusive of the discovery dispute process."

  • July 23, 2025

    Medical Device Co. Faces Investor Suit Over Sales Decline

    Eye surgery equipment manufacturer RxSight Inc. has been hit with a proposed shareholder class action accusing it of concealing "adoption challenges" and declining sales of its products, which led to a nearly 38% hit to shares when it finally disclosed the shortcomings.

  • July 23, 2025

    Dad Pulls Suit Alleging Rehab Staffer, Teen Had 'Relationship'

    The parties in a lawsuit over an alleged sexual relationship between a Utah rehab staffer and a teenage patient have stipulated to dismissing the case from Connecticut federal court, about six months after reporting that they would try to mediate the dispute.

  • July 23, 2025

    Judge Clears Mylan On 1 Novo Nordisk Patent In Wegovy Suit

    A Delaware federal judge has found that proposed labeling for a generic version of the weight loss drug Wegovy doesn't recommend doctors prescribe it in a way covered by a Novo Nordisk patent on the brand-name treatment.

  • July 23, 2025

    Bird Marella And Bioscience Client Accused Of $87M Fraud

    An investment group that includes a "Toy Story" screenwriter is suing a Culver City, California-headquartered bioscience company and its Bird Marella attorneys in California state court, accusing them of manipulating the valuation of a company whose acquisition they funded, in order to defraud investors of $87 million.

  • July 23, 2025

    Thompson Hine Adds Venable Product Liability Atty In LA

    Thompson Hine LLP is expanding its litigation team, announcing Wednesday it has brought in a Venable LLP product liability expert as a partner in its year-old Los Angeles office.

  • July 22, 2025

    FCA Draws Heavy Constitutional Fire After $1.6B J&J Verdict

    Reeling from a record fraud verdict tied to drug promotion practices, Johnson & Johnson is pursuing a sweeping constitutional challenge to the False Claims Act, and in filings this week at the Third Circuit, major industry allies rallied behind its views of whistleblower litigants usurping executive branch power.

  • July 22, 2025

    Becton Dickinson Investors Seek Final OK Of $9M Deal

    Investors in medical tech manufacturer Becton Dickinson are seeking final approval of their $9 million deal that will end derivative claims the company was damaged by its attempts to hide regulatory problems regarding sales of its Alaris pump, which would add to the list of settlements the company has entered over the alleged misrepresentations.

Expert Analysis

  • Trending At The PTAB: The Influence Of Litigation Arguments

    Author Photo

    Recent decisions from the Patent Trial and Appeal Board shed light on the varying extent to which the board considers patent owners' district court arguments, particularly with respect to the meaning of claim terms, say attorneys at Finnegan.

  • Series

    Teaching Business Law Makes Me A Better Lawyer

    Author Photo

    Teaching business law to college students has rekindled my sense of purpose as a lawyer — I am more mindful of the importance of the rule of law and the benefits of our common law system, which helps me maintain a clearer perspective on work, says David Feldman at Feldman Legal Advisors.

  • Deregulation Memo Presents Risks, Opportunities For Cos.

    Author Photo

    A recent Trump administration memo providing direction to agencies tasked with rescinding regulations under an earlier executive order — without undergoing the typical notice-and-review process — will likely create much uncertainty for businesses, though they may be able to engage with agencies to shape the regulatory agenda, say attorneys at Blank Rome.

  • Series

    Law School's Missed Lessons: Mastering Discovery

    Author Photo

    The discovery process and the rules that govern it are often absent from law school curricula, but developing a solid grasp of the particulars can give any new attorney a leg up in their practice, says Jordan Davies at Knowles Gallant.

  • Maneuvering The Weeds Of Cannabis Vertical Integration

    Author Photo

    The conversation around vertical integration has taken on new urgency as the cannabis market expands, despite federal reform remaining a distant dream, so the best strategy for cannabis operators is to approach vertical integration on a state-by-state basis, say attorneys at Sweetspot Brands.

  • Opinion

    The IRS Shouldn't Go To War Over Harvard's Tax Exemption

    Author Photo

    If the Internal Revenue Service revokes Harvard's tax-exempt status for violating established public policy — a position unsupported by currently available information — the precedent set by surviving the inevitable court challenge could undercut the autonomy and distinctiveness of the charitable sector, says Johnny Rex Buckles at Houston Law Center.

  • Series

    Playing Guitar Makes Me A Better Lawyer

    Author Photo

    Being a lawyer not only requires logic and hard work, but also belief, emotion, situational awareness and lots of natural energy — playing guitar enhances all of these qualities, increasing my capacity to do my best work, says Kosta Stojilkovic at Wilkinson Stekloff.

  • Crisis Management Lessons From The Parenting Playbook

    Author Photo

    The parenting skills we use to help our kids through challenges — like rehearsing for stressful situations, modeling confidence and taking time to reset our emotions — can also teach us the fundamentals of leading clients through a corporate crisis, say Deborah Solmor at the Wisconsin Alumni Research Foundation and Cara Peterman at Alston & Bird.

  • Justices' Labcorp Questions Explore Class Cert. Tensions

    Author Photo

    At the recent oral argument before the U.S. Supreme Court in Laboratory Corporation of America Holdings v. Davis, the justices' questioning highlighted a fundamental tension between constitutional standing requirements, the procedural framework of Rule 23, and the practical challenges of managing large, diverse classes in complex litigation, say attorneys at Winston & Strawn.

  • 4 Legislative Proposals Reflect Growing Scrutiny Of Pharma IP

    Author Photo

    Bipartisan legislative momentum in Congress, including a recent package of bills targeting exclusivity strategies that delay generic and biosimilar competition, signals growing scrutiny of life sciences intellectual property strategies, so biologics companies and investors must pay attention to new strategic, compliance and litigation risks, says Olga Berson at Thompson Coburn.

  • Series

    Adapting To Private Practice: From NY Fed To BigLaw

    Author Photo

    While the move to private practice brings a learning curve, it also brings chances to learn new skills and grow your network, requiring a clear understanding of how your skills can complement and contribute to a firm's existing practice, and where you can add new value, says Meghann Donahue at Covington.

  • 7 Considerations For Conducting Drug Clinical Trials Abroad

    Author Photo

    With continuing cuts to U.S. Food and Drug Administration staffing motivating some pharmaceutical companies to consider developing drugs abroad, it's important to understand the additional risks and compliance requirements associated with conducting clinical studies in other countries, say attorneys at Morgan Lewis.

  • Top 3 Litigation Finance Deal-Killers, And How To Avoid Them

    Author Photo

    Like all transactions, litigation finance deals can sometimes collapse, but understanding the most common reasons for failure, including a lack of trust or a misunderstanding of deal terms, can help both parties avoid problems, say Rebecca Berrebi at Avenue 33 and Boris Ziser at Schulte Roth.

  • 5th Circ. Ruling Is Latest Signal Of Shaky Qui Tam Landscape

    Author Photo

    In his recent concurring opinion in U.S. v. Peripheral Vascular Associates, a Fifth Circuit judge joined a growing list of jurists suggesting that the False Claims Act's whistleblower provisions are unconstitutional, underscoring that acceptance of qui tam relators can no longer be taken for granted, say attorneys at Miller & Chevalier.

  • How Attys Can Use A Therapy Model To Help Triggered Clients

    Author Photo

    Attorneys can lean on key principles from a psychotherapeutic paradigm known as the "Internal Family Systems" model to help manage triggered clients and get settlement negotiations back on track, says Jennifer Gibbs at Zelle.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.